Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2018 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018

NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
March 29, 2018 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress

-- Enrollment Completed in Phase 2 STARS Clinical Trial in Adults and Adolescents with Angelman Syndrome; Topline Data Expected Third Quarter 2018 -- -- Enrollment Ongoing in Phase 1b/2a Clinical...
March 15, 2018 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today...
March 15, 2018 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
March 05, 2018 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at Two Upcoming Investor Conferences

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today...
March 01, 2018 16:23 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
February 15, 2018 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today...
December 20, 2017 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome

NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
December 19, 2017 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
December 05, 2017 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...